• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

美国退伍军人在奥密克戎和德尔塔变异株流行期间感染 COVID-19 的疾病严重程度。

COVID-19 disease severity in US Veterans infected during Omicron and Delta variant predominant periods.

机构信息

VA Pittsburgh Healthcare System, Pittsburgh, PA, USA.

CRISMA Center, Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

出版信息

Nat Commun. 2022 Jun 25;13(1):3647. doi: 10.1038/s41467-022-31402-4.

DOI:10.1038/s41467-022-31402-4
PMID:35752687
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9233663/
Abstract

The SARS-CoV-2 Omicron variant is thought to cause less severe disease among the general population, but disease severity among at-risk populations is unknown. We performed a retrospective analysis using a matched cohort of United States veterans to compare the disease severity of subjects infected during Omicron and Delta predominant periods within 14 days of initial diagnosis. We identified 22,841 matched pairs for both periods. During the Omicron period, 20,681 (90.5%) veterans had mild, 1308 (5.7%) moderate, and 852 (3.7%) severe disease. During the Delta predominant period, 19,356 (84.7%) had mild, 1467 (6.4%) moderate, and 2018 (8.8%) severe disease. Moderate or severe disease was less likely during the Omicron period and more common among older subjects and those with more comorbidities. Here we show that infection with the Omicron variant is associated with less severe disease than the Delta variant in a high-risk older veteran population, and vaccinations provide protection against severe or critical disease.

摘要

奥密克戎变异株被认为在普通人群中引起的疾病较轻,但在高危人群中的疾病严重程度尚不清楚。我们使用美国退伍军人的匹配队列进行了回顾性分析,比较了在初始诊断后 14 天内奥密克戎和德尔塔变异株流行期间感染患者的疾病严重程度。我们确定了两个时期的 22841 对匹配。在奥密克戎时期,20681 名(90.5%)退伍军人患有轻度疾病,1308 名(5.7%)患有中度疾病,852 名(3.7%)患有重度疾病。在德尔塔为主的时期,19356 名(84.7%)患有轻度疾病,1467 名(6.4%)患有中度疾病,2018 名(8.8%)患有重度疾病。奥密克戎时期的中度或重度疾病较少,而在年龄较大的患者和合并症较多的患者中更为常见。在这里,我们表明在高危老年退伍军人中,与德尔塔变异株相比,感染奥密克戎变异株与疾病较轻相关,而疫苗接种可预防重症或危重症疾病。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e1d/9233663/9d02ff51694c/41467_2022_31402_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e1d/9233663/9d02ff51694c/41467_2022_31402_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e1d/9233663/9d02ff51694c/41467_2022_31402_Fig1_HTML.jpg

相似文献

1
COVID-19 disease severity in US Veterans infected during Omicron and Delta variant predominant periods.美国退伍军人在奥密克戎和德尔塔变异株流行期间感染 COVID-19 的疾病严重程度。
Nat Commun. 2022 Jun 25;13(1):3647. doi: 10.1038/s41467-022-31402-4.
2
Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods - United States, December 2020-January 2022.疾病严重程度和医疗保健利用趋势在奥密克戎变异株早期与之前 SARS-CoV-2 高传播期相比-美国,2020 年 12 月至 2022 年 1 月。
MMWR Morb Mortal Wkly Rep. 2022 Jan 28;71(4):146-152. doi: 10.15585/mmwr.mm7104e4.
3
COVID-19 disease severity in persons infected with the Omicron variant compared with the Delta variant in Qatar.卡塔尔感染奥密克戎变异株与感染德尔塔变异株的患者 COVID-19 疾病严重程度比较。
J Glob Health. 2022 Jul 6;12:05032. doi: 10.7189/jogh.12.05032.
4
Coronavirus Disease 2019 Disease Severity in Children Infected With the Omicron Variant.2019 年冠状病毒病在感染奥密克戎变异株的儿童中的严重程度。
Clin Infect Dis. 2022 Aug 24;75(1):e361-e367. doi: 10.1093/cid/ciac275.
5
SARS-CoV-2 infection following booster vaccination: Illness and symptom profile in a prospective, observational community-based case-control study.接种加强针后感染 SARS-CoV-2:一项前瞻性、基于社区的病例对照研究中的疾病和症状特征。
J Infect. 2023 Dec;87(6):506-515. doi: 10.1016/j.jinf.2023.08.009. Epub 2023 Sep 28.
6
Clinical Characteristics and Outcomes of Children With SARS-CoV-2 Infection During the Delta and Omicron Variant-Dominant Periods in Korea.韩国德尔塔和奥密克戎变异株流行期间儿童感染 SARS-CoV-2 的临床特征和结局。
J Korean Med Sci. 2023 Mar 6;38(9):e65. doi: 10.3346/jkms.2023.38.e65.
7
Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.疫苗对 Alpha、Delta 或奥密克戎变异株引起的 SARS-CoV-2 感染或 COVID-19 住院的有效性:一项全国性丹麦队列研究。
PLoS Med. 2022 Sep 1;19(9):e1003992. doi: 10.1371/journal.pmed.1003992. eCollection 2022 Sep.
8
Effectiveness of mRNA COVID-19 vaccines against Omicron and Delta variants in a matched test-negative case-control study among US veterans.mRNA COVID-19 疫苗在一项美国退伍军人配对病例对照研究中对奥密克戎和德尔塔变异株的有效性。
BMJ Open. 2022 Aug 3;12(8):e063935. doi: 10.1136/bmjopen-2022-063935.
9
Severity of Illness in Persons Infected With the SARS-CoV-2 Delta Variant vs Beta Variant in Qatar.在卡塔尔感染 SARS-CoV-2 的德尔塔变异株和贝塔变异株患者的疾病严重程度。
JAMA Intern Med. 2022 Feb 1;182(2):197-205. doi: 10.1001/jamainternmed.2021.7949.
10
Comparison of clinical characteristics and outcomes of critically ill adults with SARS-CoV-2 infection during Delta and Omicron variant predominance periods: a single-hospital retrospective cohort study.德尔塔和奥密克戎变异株流行期间危重症成人 COVID-19 感染的临床特征和结局比较:单中心回顾性队列研究。
BMJ Open Respir Res. 2023 Feb;10(1). doi: 10.1136/bmjresp-2022-001274.

引用本文的文献

1
Applying two approaches to detect unmeasured confounding due to time-varying variables in a self-controlled risk interval design evaluating COVID-19 vaccine safety signals, using myocarditis as a case example.在以心肌炎为例的自我对照风险区间设计中,应用两种方法来检测因随时间变化的变量导致的未测量混杂因素,以评估新冠病毒疫苗的安全信号。
Am J Epidemiol. 2025 Jan 8;194(1):208-219. doi: 10.1093/aje/kwae172.
2
Safety and efficacy of COVID-19 vaccination in the Chinese population with pulmonary lymphangioleiomyomatosis: a single-center retrospective study.中国人群肺淋巴管肌瘤病患者 COVID-19 疫苗接种的安全性和有效性:一项单中心回顾性研究。
Orphanet J Rare Dis. 2024 Jul 3;19(1):247. doi: 10.1186/s13023-024-03260-4.
3

本文引用的文献

1
Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design.苏格兰关注的奥密克戎变异株的严重程度和疫苗加强针预防有症状疾病的效果(EAVE II):一项具有巢式病例对照研究设计的全国队列研究。
Lancet Infect Dis. 2022 Jul;22(7):959-966. doi: 10.1016/S1473-3099(22)00141-4. Epub 2022 Apr 22.
2
Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study.比较分析英国住院和死亡风险与 SARS-CoV-2 奥密克戎(B.1.1.529)和德尔塔(B.1.617.2)变异株的关系:一项队列研究。
Lancet. 2022 Apr 2;399(10332):1303-1312. doi: 10.1016/S0140-6736(22)00462-7. Epub 2022 Mar 16.
3
Nirmatrelvir/ritonavir or Molnupiravir for treatment of non-hospitalized patients with COVID-19 at risk of disease progression.
尼马曲韦/利托那韦或莫努匹韦用于治疗有疾病进展风险的非住院 COVID-19 患者。
PLoS One. 2024 Jun 6;19(6):e0298254. doi: 10.1371/journal.pone.0298254. eCollection 2024.
4
Comparing COVID-19 severity in patients hospitalized for community-associated Delta, BA.1 and BA.4/5 variant infection.比较因社区获得性 Delta、BA.1 和 BA.4/5 变异株感染住院的患者的 COVID-19 严重程度。
Front Public Health. 2024 Feb 21;12:1294261. doi: 10.3389/fpubh.2024.1294261. eCollection 2024.
5
Comparison of Omicron and Delta Variants of SARS-CoV-2: A Systematic Review of Current Evidence.奥密克戎和德尔塔变异株的比较:当前证据的系统评价。
Infect Disord Drug Targets. 2024;24(7):e050324227686. doi: 10.2174/0118715265279242240216114548.
6
Differential Ability of Spike Protein of SARS-CoV-2 Variants to Downregulate ACE2.SARS-CoV-2 变异株 Spike 蛋白下调 ACE2 的能力差异。
Int J Mol Sci. 2024 Jan 22;25(2):1353. doi: 10.3390/ijms25021353.
7
The Suitability of RNA from Positive SARS-CoV-2 Rapid Antigen Tests for Whole Virus Genome Sequencing and Variant Identification to Maintain Genomic Surveillance.新冠病毒快速抗原检测阳性样本中的RNA用于全病毒基因组测序和变异株鉴定以维持基因组监测的适用性
Diagnostics (Basel). 2023 Dec 7;13(24):3618. doi: 10.3390/diagnostics13243618.
8
Clinical course and management of COVID-19 in the era of widespread population immunity.广泛人群免疫时代下的 COVID-19 临床病程和管理。
Nat Rev Microbiol. 2024 Feb;22(2):75-88. doi: 10.1038/s41579-023-01001-1. Epub 2023 Dec 19.
9
The neurobiology of SARS-CoV-2 infection.SARS-CoV-2 感染的神经生物学。
Nat Rev Neurosci. 2024 Jan;25(1):30-42. doi: 10.1038/s41583-023-00769-8. Epub 2023 Dec 4.
10
SARS-CoV-2 genomics and impact on clinical care for COVID-19.SARS-CoV-2 基因组学及其对 COVID-19 临床护理的影响。
J Antimicrob Chemother. 2023 Nov 23;78(Suppl 2):ii25-ii36. doi: 10.1093/jac/dkad309.
Vaccine Effectiveness of 3 Versus 2 Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccines in a High-Risk National Population.高风险人群中 3 剂与 2 剂严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)mRNA 疫苗的疫苗有效性。
Clin Infect Dis. 2022 Aug 24;75(1):e579-e584. doi: 10.1093/cid/ciac178.
4
Effectiveness of Homologous or Heterologous Covid-19 Boosters in Veterans.同源或异源新冠病毒加强针在退伍军人中的有效性。
N Engl J Med. 2022 Apr 7;386(14):1375-1377. doi: 10.1056/NEJMc2200415. Epub 2022 Feb 9.
5
Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022.与德尔塔变异株相比,报告的 COVID-19 病例中感染 SARS-CoV-2 奥密克戎 BA.1 变异株的住院风险降低,挪威,2021 年 12 月至 2022 年 1 月。
Euro Surveill. 2022 Jan;27(4). doi: 10.2807/1560-7917.ES.2022.27.4.2200077.
6
Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study.南非对 SARS-CoV-2 奥密克戎变异株临床严重程度的早期评估:一项数据关联研究。
Lancet. 2022 Jan 29;399(10323):437-446. doi: 10.1016/S0140-6736(22)00017-4. Epub 2022 Jan 19.
7
Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa.南非 SARS-CoV-2 奥密克戎变异株的快速流行扩张。
Nature. 2022 Mar;603(7902):679-686. doi: 10.1038/s41586-022-04411-y. Epub 2022 Jan 7.
8
Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa.BNT162b2疫苗在南非针对奥密克戎变异株的有效性
N Engl J Med. 2022 Feb 3;386(5):494-496. doi: 10.1056/NEJMc2119270. Epub 2021 Dec 29.
9
SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells.与德尔塔变异株相比,SARS-CoV-2 奥密克戎变异株在表达 TMPRSS2 的细胞中的复制和融合活性较低。
Emerg Microbes Infect. 2022 Dec;11(1):277-283. doi: 10.1080/22221751.2021.2023329.
10
Covid-19: Early studies give hope omicron is milder than other variants.新冠疫情:早期研究带来希望,奥密克戎毒株比其他变种毒株症状更轻。
BMJ. 2021 Dec 23;375:n3144. doi: 10.1136/bmj.n3144.